Cleveland Clinic launches first-of-its kind preventive breast cancer vaccine study
Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
This phase I trial is designed to determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer and to characterize and optimize the body's immune response.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Pharmaceuticals | Study | Vaccines